{
  "drug_id": "D002",
  "drug_name": "Bromilix",
  "indication": "Condition-Y",
  "modality": "monoclonal antibody",
  "mechanism": "selective pathway inhibitor",
  "moa_short": "Inhibits a disease-relevant signaling pathway to reduce downstream activation.",
  "formulation": "vial for infusion",
  "route": "intravenous",
  "regimen": "10 mg/kg Q4W",
  "trial_id": "AMGN-D002-401",
  "phase": "Phase 3",
  "arms": [
    {
      "name": "Bromilix 10 mg/kg Q4W",
      "n": 194,
      "dose": "10 mg/kg Q4W"
    },
    {
      "name": "Placebo",
      "n": 186,
      "dose": "matching regimen"
    }
  ],
  "population": "Adults with moderate-to-severe Condition-Y with inadequate response to standard therapy.",
  "key_inclusion": [
    "Confirmed diagnosis per protocol definition",
    "Baseline disease activity above threshold",
    "Stable background therapy for \u22654 weeks"
  ],
  "key_exclusion": [
    "Severe uncontrolled comorbidity (per protocol)",
    "Recent major surgery within 12 weeks",
    "Known hypersensitivity to components"
  ],
  "results": {
    "endpoint_primary": "Proportion achieving Response-50 at Week 16",
    "endpoint_secondary": "Quality-of-life improvement at Week 12",
    "primary_effect": "52.5% vs 27.8% (\u0394 24.7%)",
    "primary_pvalue": 0.04649170394403939,
    "primary_ci": "[16.7%, 32.7%]",
    "secondary_effect": "Numerically favored active arm; supportive trend",
    "discontinuation_rate_pct": 3.7366950971619284
  },
  "safety": {
    "common_ae": [
      [
        "Nausea",
        7.931071198190044
      ],
      [
        "Headache",
        6.38193719148645
      ],
      [
        "Elevated ALT",
        6.04344073239551
      ],
      [
        "Rash",
        2.0
      ],
      [
        "Diarrhea",
        2.0
      ],
      [
        "Injection-site reaction",
        2.0
      ]
    ],
    "serious_ae_rate_pct": 3.6095284192712147,
    "discontinuation_ae_rate_pct": 3.2810266565070654,
    "warnings": [
      "Monitor for hypersensitivity reactions.",
      "Assess for infection risk in susceptible patients.",
      "Consider hepatic monitoring if clinically indicated."
    ],
    "contraindications": [
      "Known hypersensitivity to active substance or excipients."
    ]
  },
  "monitoring": [
    "Baseline labs per protocol (CBC, CMP)",
    "Periodic assessment of liver enzymes",
    "Clinical monitoring for infections"
  ],
  "version": "v1.4",
  "doc_date": "2025-12-26"
}